[1] 刘伦飞,郑敏.CXCR3及其配体与皮肤病.国外医学皮肤性病分册,2002,28:166-168. [2] Becker H, Schauer U, Helmke K.B lymphocyte activation by insoluble anti-μ antibodies in patients with systemic lupus erythematosus. Clin Exp Immunol, 1986,66:365-372. [3] Bombardier C, Gladman DD, Urowitz MB,et al.Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992,35:630-640. [4] 郑敏,朱铁城.SLE患者B淋巴细胞增殖功能测定及其临床意义.中华皮肤科杂志,1990,23:90-92. [5] Arenberg DA, Kunkel SL, Polverini PJ, et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med, 1996,184:981-992. [6] Khalil M, Inaba K, Steinman R, et al. T cell studies in a peptideinduced model of systemic lupus erythematosus. J Immunol, 2001,166:1667-1674. [7] Csiszar A, Nagy G, Gergely P, et al. Increased interferon-gamma(IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol, 2000,122:464-470. [8] Campbell JD, Stinson MJ, Simons FE, et al. In vivo stability of human chemokine and chemokine receptor expression.Hum Immunol,2001,62:668-678. [9] Alexopoulos E, Seron D, Hartley RB, et al. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int, 1990,37:100-109. [10] Akahoshi M, Nakashima H, Tanaka Y,et al.Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum, 1999,42:1644-1648. [11] Masutani K, Akahoshi M, Tsuruya K, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum, 2001,44:2097-2106. [12] Romagnani P, Beltrame C, Annunziato F, et al. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis.J Am Soc Nephrol, 1999,10:2518-2526. |